Skip to main content
SpringerLink
Log in

Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation?

  • Letter to the Editor
  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Pfeiler G, Hlauschek D, Mayer EL et al (2023) Impact of BMI in patients with early hormone receptor-positive breast cancer receiving endocrine therapy with or without palbociclib in the PALLAS trial. JCO. https://doi.org/10.1200/JCO.23.00126

    Article  Google Scholar 

  2. Roncato R, Peruzzi E, Gerratana L et al (2023) Clinical impact of body mass index on palbociclib treatment outcomes and effect on exposure. Biomed Pharmacother 164:114906. https://doi.org/10.1016/j.biopha.2023.114906

    Article  PubMed  CAS  Google Scholar 

  3. Gnant M, Dueck AC, Frantal S et al (2022) Adjuvant palbociclib for early breast cancer: the PALLAS trial results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol 40:282–293. https://doi.org/10.1200/JCO.21.02554

    Article  PubMed  CAS  Google Scholar 

Download references

Funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Author information

Authors and Affiliations

  1. Department of Medicine, University of Udine, Udine, Italy

    Rossana Roncato & Fabio Puglisi

  2. Department of Medical Oncology, CRO Aviano National Cancer Institute, IRCCS, Aviano, Italy

    Fabio Puglisi & Lorenzo Gerratana

Authors
  1. Rossana Roncato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Fabio Puglisi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Lorenzo Gerratana
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

All authors contributed to the study conception and design. All authors read and approved the final manuscript.

Corresponding author

Correspondence to Lorenzo Gerratana.

Ethics declarations

Competing interests

Conflicts of Interest and Source of Funding: FP has received honoraria from Amgen—Astrazeneca—Daiichi Sankyo—Celgene—Eisai—Eli Lilly-—Exact Sciences—Gilead—Ipsen—Menarini—MSD—Novartis—Pierre Fabre—Pfizer—Roche—Seagen—Takeda—Viatris. FP is currently receiving research grants from Astrazeneca, EISAI, and Roche. LG has received honoraria from AstraZeneca, Daiichi Sankyo, Eli Lilly, GlaxoSmithKline, Incyte, Novartis, Pfizer, Menarini Stemmline, and AbbVie. LG is currently receiving research grants from Menarini Silicon Biosystems.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Roncato, R., Puglisi, F. & Gerratana, L. Body mass index impacts adverse events and drug plasma concentration: should dose intensity be included in the palbociclib equation?. Breast Cancer Res Treat 203, 183–184 (2024). https://doi.org/10.1007/s10549-023-07154-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10549-023-07154-0

Search

Navigation